Tempest Therapeutics, Inc. Common Stock
TPSTTempest Therapeutics, Inc. (TPST) is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company aims to identify and advance novel immuno-oncology and targeted agents, leveraging a deep understanding of tumor biology to create treatments that improve patient outcomes.
Company News
Tempest Therapeutics will present updated clinical data from its REDEEM-1 Phase 1/2a trial of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy for relapsed/refractory multiple myeloma, at the International Society for Cell & Gene Therapy Scientific Annual Meeting in Dublin (May 6-9, 2026). Earlier interim data showed a 100% complete response r...
Tempest Therapeutics selected Cincinnati Children's Applied Gene and Cell Therapy Center as its manufacturing partner for technology transfer of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy for relapsed/refractory multiple myeloma. The partnership supports preparation for a planned U.S. registrational study with IND filing targeted for Q4 ...
Tempest Therapeutics has agreed to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, which is expected to extend the company's operational runway to mid-2027 and diversify its clinical-stage pipeline.
Tempest Therapeutics plans to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, expanding its clinical-stage pipeline and extending its operational runway to mid-2027. The acquisition includes a clinical-stage CD19/BCMA dual-CAR T program and is expected to close in early 2026.
The advanced liver cancer market is positioned for strong growth, with over 50 companies developing 52+ pipeline drugs, focusing on innovative targeted therapies and immuno-oncology combinations to improve treatment outcomes.
